BiotechTube

NKTR-118 + Ketoconazole

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioavailability

Conditions

Bioavailability, Healthy Volunteers, Drug- Drug Interactions

Trial Timeline

Feb 1, 2012 → Apr 1, 2012

NCT ID
NCT01520896

About NKTR-118 + Ketoconazole

NKTR-118 + Ketoconazole is a phase 1 stage product being developed by AstraZeneca for Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT01520896. Target conditions include Bioavailability, Healthy Volunteers, Drug- Drug Interactions.

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01520896Phase 1Completed

Competing Products

20 competing products in Bioavailability

See all competitors
ProductCompanyStageHype Score
solifenacin succinate suspension + solifenacin succinate tabletAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
IpragliflozinAstellas PharmaPhase 1
29
HetrombopagJiangsu Hengrui MedicinePhase 1
29
ABT-450/r/ABT-267AbbViePhase 1
29
ABT-333AbbViePhase 1
29
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2AstraZenecaPhase 1
29
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orallyAstraZenecaPhase 1
29
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
29
selumetinib 75mg single doseAstraZenecaPhase 1
29
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tubeAstraZenecaPhase 1
29
AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423AstraZenecaPhase 1
29
Fostamatinib + Fostamatinib + Fostamatinib + FostamatinibAstraZenecaPhase 1
29
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcgAstraZenecaPhase 1
29
D1400147 + D14000136 + D14000137 + Epanova®AstraZenecaPhase 1
29
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of waterAstraZenecaPhase 1
29
TEPEZZA + EDPAmgenPhase 1
29
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavirPfizerPhase 1
29
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332PfizerPhase 1
29